Notably, recent clinical trials have shown that checkpoint inhibition with anti-PD-1 and PD-L1 antibodies could reactivate cytotoxic T cells to work against cancer cells, such as nivolumab and pembrolizumab, is effective in treating recurrent or metastatic HNSCC [1,52,53]. This evidence concerns the gene CD274 and cancer.